|
Video: What is a Stock Split?
|
|
Karuna Therapeutics is a clinical-stage biopharmaceutical company that focuses on transformative medicines for people living with psychiatric and neurological conditions. Co.'s proprietary product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT combines xanomeline, a muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. Co. is developing KarXT for the treatment of psychosis in adults with schizophrenia as well as for the treatment of psychosis in Alzheimer's disease. According to our KRTX split history records, Karuna Therapeutics has had 0 splits. | |
|
Karuna Therapeutics (KRTX) has 0 splits in our KRTX split history database.
Looking at the KRTX split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Karuna Therapeutics shares, starting with a $10,000 purchase of KRTX, presented on a split-history-adjusted basis factoring in the complete KRTX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/01/2019 |
|
End date: |
03/18/2024 |
|
Start price/share: |
$21.00 |
|
End price/share: |
$329.83 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
1,470.62% |
|
Average Annual Total Return: |
79.28% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$157,077.73 |
|
Years: |
4.72 |
|
|
|
|
|